KOSDAQBiotech & Pharma215600

SillaJen

₩1,912▲ 2.63%2026-11-18 close
Market Cap
₩264.9B
Turnover
₩800M
Volume
430K
Shares out.
140M
PER
—
PBR
2.7×
EPS
-₩153
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

SillaJen: Pipeline Pivot and Narrowing Losses

SillaJen's operating loss narrowed to KRW 3.85 billion in the third quarter of 2026, but the company has posted losses for five straight quarters, so the pace of recovery depends on BAL0891 clinical progress and growth in pharma sales.

  1. 1

    Revenue rose 134.9% year on year to KRW 9.23 billion in 2025, while the operating loss narrowed to KRW 25.6 billion.

  2. 2

    Third-quarter 2026 revenue reached KRW 3.1 billion, up 12.0% from a year earlier, and the operating loss narrowed to KRW 3.85 billion.

  3. 3

    BAL0891 received FDA orphan drug designation for acute myeloid leukemia, and early clinical data were presented at ASCO in June 2026.

  4. 4

    The debt ratio stood at 6.1% at the end of 2025 with total equity of KRW 110.1 billion, yet operating cash flow has been negative every year from 2022 to 2025.

  5. 5

    Shareholder net losses over the last four quarters total KRW 21.2 billion, so PER cannot be calculated, and the price-to-book ratio sits in a range that carries a premium to net assets.

02

Business structure

SillaJen is a biotech company focused on developing anticancer drugs. Its main pipeline includes the solid tumor candidate BAL0891, the immuno-oncology agent Pexa-Vec, and the next-generation oncolytic virus platform SJ-600 series.

The FDA granted BAL0891 orphan drug designation for acute myeloid leukemia (AML), and early clinical results were presented at the American Society of Clinical Oncology (ASCO) meeting in June 2026.

In those results, the recommended phase 2 dose for monotherapy was set at 160mg, and an eight-patient cohort treated with paclitaxel reached a disease control rate of 87.5%.

Pexa-Vec is being developed for renal cell carcinoma, melanoma, and prostate cancer according to a 2025 press report, and the phase 3 trial in liver cancer was halted in August 2019. On the platform side, a study of the intravenously administered oncolytic virus SJ-650 was accepted by a journal in January 2026.

On the sales side, a pharma division was set up after the merger of Woosung Pharm, and drug sales in the first half of 2026 reached KRW 4.9 billion, up 145.0% year on year. That accounted for most of the company's total first-half revenue of KRW 5.1 billion.

According to press reports, pharma division sales exceeded KRW 9 billion in 2025 and were expected to top KRW 10 billion in 2026. Technology licensing centers on BAL0891 and the SJ-600 series, and in October 2026 SillaJen was selected for the second round of the national new drug development project.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.8B-₩6.1B−222.0%
2025Q4₩2.9B-₩8.2B−280.2%
2026Q1₩2.9B-₩5.6B−198.1%
2026Q2₩2.2B-₩6.2B−275.5%
2026Q3₩3.1B-₩3.8B−124.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩5B-₩24.5B-₩24.6B−488.2%−31.2%31.0%
2023₩3.9B-₩21.3B-₩20.4B−541.8%−35.5%33.9%
2024₩3.9B-₩26.8B-₩26.5B−681.7%−20.1%13.0%
2025₩9.2B-₩25.6B-₩24.2B−277.4%−22.0%6.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Based on disclosed results, revenue went from KRW 5.01 billion in 2022 to KRW 3.94 billion in 2023 (down 21.4% year on year) and KRW 3.93 billion in 2024 (down 0.3%), before jumping to KRW 9.23 billion in 2025 (up 134.9%). Among 2022 to 2025, 2025 was the largest year and 2024 the smallest.

Operating losses were KRW 24.5 billion in 2022, KRW 21.3 billion in 2023 (losses continued, with the loss narrowing), KRW 26.8 billion in 2024 (losses continued, with the loss widening), and KRW 25.6 billion in 2025 (losses continued, with the loss narrowing).

The company has been in the red for four consecutive years from 2022 through 2025. The operating margin moved from -488.2% in 2022 to -541.8% in 2023, -681.7% in 2024, and -277.4% in 2025. The 2025 improvement owed more to revenue more than doubling than to a sharp cut in the loss.

According to press reports, pharma division sales exceeded KRW 9 billion in 2025. Net loss attributable to shareholders was KRW 24.6 billion in 2022, KRW 20.4 billion in 2023, KRW 26.5 billion in 2024, and KRW 24.2 billion in 2025.

Net loss including non-controlling interests is disclosed at the same levels for each year. The debt ratio fell from 31.0% in 2022 and 33.9% in 2023 to 13.0% in 2024 and 6.1% in 2025. At the end of 2025, total equity was KRW 110.1 billion and total liabilities were KRW 6.69 billion.

Operating cash flow was -KRW 22.1 billion in 2022, -KRW 17 billion in 2023, -KRW 17.8 billion in 2024, and -KRW 22.5 billion in 2025, negative every year with the outflow widening in 2025.

Quarterly revenue was KRW 2.76 billion in the third quarter of 2025, KRW 2.91 billion in the fourth quarter (up 5.3% from the prior quarter), KRW 2.85 billion in the first quarter of 2026, KRW 2.24 billion in the second quarter (down 21.3% quarter on quarter), and KRW 3.1 billion in the third quarter of 2026 (up 38.0% quarter on quarter and 12.0% year on year).

The operating loss widened from KRW 6.14 billion in the third quarter of 2025 to KRW 8.16 billion in the fourth quarter, narrowed to KRW 5.65 billion in the first quarter of 2026, widened again to KRW 6.18 billion in the second quarter, and narrowed to KRW 3.85 billion in the third quarter of 2026.

Net loss attributable to shareholders was KRW 2.97 billion in the third quarter of 2026, with the loss narrowing from a year earlier, and totaled KRW 21.2 billion over the last four quarters.

Based on disclosed results, the company has posted losses for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.

05

Industry analysis

Anticancer drug development carries high failure risk at each clinical stage, and whether technology licensing deals close has a large effect on how companies are valued.

After the 2019 halt of the Pexa-Vec phase 3 liver cancer trial, SillaJen went through a management change and litigation, and its pipeline focus shifted from Pexa-Vec to BAL0891.

Press reports describe weak conditions in the biotech sector, while SillaJen has been building expectations through clinical and academic milestones.

Peers often cited for comparison include LigaChem Biosciences and ABL Bio, which have anticancer licensing experience, and Alteogen, known for platform technology licensing.

Compared with these companies, SillaJen's clinical programs are still at an early stage, and its licensing targets center on the SJ-600 series and BAL0891. Both Pexa-Vec and BAL0891 target solid tumors, so comparing trial design with competing agents matters.

The oncolytic virus platform's intravenous and repeated dosing potential is at a validation stage, and analysts argue this validation could affect negotiating leverage in licensing.

Few listed biotech companies in Korea run a pharma sales business alongside pipeline development, so SillaJen's revenue structure differs from that of pipeline-focused peers. Sector conditions and company-specific factors overlap, so sector averages alone make it hard to judge its results.

06

Outlook

The company said BAL0891 has established grounds for entering phase 2 trials. The maximum tolerated dose for monotherapy was set at 240mg and the recommended phase 2 dose at 160mg, and the company plans to apply the 80mg safety margin between the two doses in future clinical development.

In January 2026, a study of SJ-650 was accepted by a journal, and later that year ESMO 2026 accepted a poster presenting phase 1 results for BAL0891. Press reports say clinical and academic achievements continued across two core pipeline assets in the first half of 2026.

A press report from October 2025 said combination trials of BAL0891 with an immune checkpoint inhibitor could begin in earnest after FDA approval. Press reports project that pharma division sales will top KRW 10 billion in 2026.

Following the selection announced on October 8, 2026 for the second round of the national new drug development project, agreement signing and revised plan submission remain, with detailed timing to be announced by the project office.

The next periodic report is the 2026 annual business report, which will disclose full-year 2026 revenue, operating loss, and operating cash flow. Publicly available material on Pexa-Vec's future development direction is limited, so pipeline assessment rests more heavily on BAL0891 clinical results.

07

Valuation

PER
—
PBR
2.7×
ROE
-19.7%
EPS
-₩153
BPS
₩706
Dividend per share
₩0

Current valuation reads as weighted toward net assets and pipeline expectations rather than current earnings. Because shareholder net losses have continued over the last four quarters, PER cannot be calculated.

The price-to-book ratio sits well above 1x, which reflects a premium to net assets that is read as market expectations for the pipeline. Shareholders' equity at the end of 2025 was KRW 110.1 billion and nearly all of it attributable to shareholders, which keeps net-asset comparisons relatively straightforward.

No dividend has been paid, so the dividend yield is below the sector average. Without earnings-based multiples, the speed of earnings turnaround and clinical progress become the key variables for interpreting valuation. No year in the disclosed period shows a shift from losses to profit, which limits earnings-based comparison.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Clinical signals and regulatory designation

BAL0891 received FDA orphan drug designation for acute myeloid leukemia. At ASCO in June 2026, the recommended phase 2 dose for monotherapy was set at 160mg, and among eight patients treated at 120mg or higher, one achieved a complete response and one a partial response.

The paclitaxel combination cohort of eight patients reported a disease control rate of 87.5%. The company said these results provide grounds for entering phase 2.

Expanding revenue base

Revenue rose 134.9% to KRW 9.23 billion in 2025. Third-quarter 2026 revenue reached KRW 3.1 billion, up 12.0% from a year earlier. According to press reports, drug sales in the first half of 2026 reached KRW 4.9 billion, up 145.0% year on year. Press coverage describes the pharma division as a source of cash generation separate from new drug development.

Narrowing losses and low leverage

The operating loss narrowed to KRW 3.85 billion in the third quarter of 2026, down from a year earlier. The net loss attributable to shareholders also narrowed to KRW 2.97 billion. The debt ratio fell from 31.0% in 2022 to 6.1% in 2025, and total liabilities at the end of 2025 were KRW 6.69 billion. The relatively light debt burden supports the company's capacity to fund its pipeline.

09

Bear factors

Cash outflows and cumulative losses

Operating cash flow was negative every year from 2022 to 2025, and the outflow widened to -KRW 22.5 billion in 2025 from -KRW 17.8 billion in 2024. The company has posted losses for five consecutive quarters since the third quarter of 2025. Shareholder net losses over the last four quarters total KRW 21.2 billion. Even with higher revenue in 2025, the operating loss remained at KRW 25.6 billion.

Legacy of the Pexa-Vec trial halt

The phase 3 Pexa-Vec trial in liver cancer was halted in August 2019 following a recommendation from an independent data monitoring committee, and the share price fell sharply afterward. Around the same time, an executive's share sales before the recommendation raised allegations of insider information use. BAL0891 remains at an early clinical stage, so there is no assurance it will avoid a similar setback.

Governance and litigation burden

After management misconduct allegations including embezzlement and breach of trust came to light, minority shareholders sued former executives and the Korea Exchange for damages, and lost on appeal. Former CEO Moon Eun-sang stepped down and Han Sang-gyu took over as CEO.

Former DB Financial Investment executives involved in the design of the BW subscription were also sentenced to prison in the appellate court.

10

Risk factors

Clinical risk

The 2026 ASCO data for BAL0891 come from an early study with a small sample, with only eight patients treated at 120mg or higher as monotherapy. Orphan drug designation does not guarantee approval or licensing deals. The 2019 halt of the Pexa-Vec liver trial shows that clinical results can diverge from expectations.

Funding and cash flow risk

Operating cash flow has been negative every year from 2022 to 2025, with the outflow reaching -KRW 22.5 billion in 2025. Total equity at the end of 2025 was KRW 110.1 billion, all attributable to shareholders.

With cash outflows continuing, the allocation between pipeline spending and operating costs becomes a key variable.

Governance and legal risk

Following embezzlement and breach of trust allegations, legal proceedings continued, and recent changes include a CEO departure and a new controlling shareholder. Minority shareholders also lost a damages suit on appeal.

How governance changes affect R&D timelines will need to be tracked through disclosures and investor relations materials.

11

What to watch next

  1. After December 2026 (timing set by the project office)

    Confirm the agreement signing and revised plan submission for the second round of the national new drug development project, which marks whether the candidate research task moves forward.

  2. End of March 2027

    The 2026 annual business report will disclose full-year 2026 revenue, operating loss, and operating cash flow. Key checks are whether the operating loss falls below KRW 25.6 billion and whether operating cash outflows continue.

  3. May 15, 2027

    This is the filing deadline for the first-quarter 2027 report. The checkpoints are whether quarterly revenue holds near KRW 3.1 billion and whether the net loss attributable to shareholders stays below the KRW 2.97 billion posted in the third quarter of 2026.

  4. During 2027 (company timing not yet announced)

    The next checkpoints are the announcement of BAL0891 phase 2 entry and follow-up data from the AML trial. Whether phase 2 begins will be the next benchmark for assessing pipeline value.

12

Overall view

SillaJen's revenue more than doubled to KRW 9.23 billion in 2025, and its operating loss narrowed to KRW 3.85 billion in the third quarter of 2026, so the losses are moving in a narrower direction.

However, operating cash flow has been negative every year from 2022 through 2025, and the company has posted losses for five consecutive quarters since the third quarter of 2025. Its balance sheet shows a debt ratio of 6.1% and total equity of KRW 110.1 billion at the end of 2025, a relatively light debt burden.

In the pipeline, BAL0891 has FDA orphan drug designation and early ASCO data, but it remains an early-stage trial with a small sample. Pexa-Vec's liver cancer phase 3 trial was halted in 2019, and the company has since shifted its focus to BAL0891.

Governance is in transition through a CEO departure and a change in the controlling shareholder, and litigation history remains. On a price-to-book basis, the market is pricing in a premium to net assets, so pipeline value and the pace of earnings recovery are the central questions in valuation.

The next checkpoints are full-year operating loss in the 2026 annual business report, quarterly results for the first quarter of 2027, and the announcement of BAL0891 phase 2 entry.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. edaily.co.kr
  2. edaily.co.kr
  3. edaily.co.kr
  4. medicaltimes.com
  5. asiae.co.kr
  6. medipana.com
  7. pharmnews.com
  8. sisajournal-e.com
  9. fntimes.com
  10. edaily.co.kr
  11. businesspost.co.kr
  12. hankyung.com
  13. cbci.co.kr
  14. eureka.hankyung.com
  15. judal.co.kr
  16. v.daum.net
  17. judal.co.kr
  18. cbci.co.kr

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis